Oleanolic acid inhibits epithelial–mesenchymal transition of hepatocellular carcinoma by promoting iNOS dimerization

H Wang, W Zhong, J Zhao, H Zhang, Q Zhang… - Molecular cancer …, 2019 - AACR
Oleanolic acid exhibits extensive pharmacologic activities and takes significant antitumor
effects. Its pharmacologic mechanism, however, still remained to be further clarified. In this …

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma

YS Guan, Q He - Expert opinion on pharmacotherapy, 2011 - Taylor & Francis
Introduction: Sorafenib is a novel oral bis-aryl urea compound that has proven survival
benefit in patients with advanced hepatocellular carcinoma (HCC), for which several …

A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis

M Ikeda, T Okusaka, J Furuse, S Mitsunaga… - Cancer chemotherapy …, 2013 - Springer
Purpose The objective of this study was to evaluate the response rate, survival, and adverse
effects of hepatic arterial infusion chemotherapy (HAIC) using cisplatin in patients with …

[HTML][HTML] Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells in vitro

LL Yin, XM Wen, QH Lai, J Li… - Oncology …, 2018 - spandidos-publications.com
Lenalidomide is an immunomodulatory drug and possesses anti-angiogenic and
immunomodulatory activities against multiple myeloma. The present study assessed the in …

Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK

Y Gao, HX Li, LT Xu, P Wang, LY Xu, L Cohen… - Molecular biology …, 2012 - Springer
The purpose of this study was to investigate the effect of bufalin on the anti-proliferative
activity of sorafenib in the human hepatocellular carcinoma (HCC) cell lines PLC/PRF/5 and …

[HTML][HTML] Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts

C Eicher, A Dewerth, J Thomale, V Ellerkamp… - British journal of …, 2013 - nature.com
Background: Sorafenib has recently been shown to reduce tumour growth in
hepatoblastoma (HB) xenografts. The effect of a combined administration with cytostatic …

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma

A Hagihara, M Ikeda, H Ueno, C Morizane… - Cancer …, 2014 - Wiley Online Library
The aims of this study were to evaluate the frequency of dose‐limiting toxicities and to find
the recommended dose of combination chemotherapy with sorafenib and transcatheter …

Phase I study of sorafenib in combination with intermittent hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma

M Ishizaki, M Kaibori, K Matsui, H Ikeda… - Cancer …, 2017 - Taylor & Francis
Objectives: We conducted a phase I study of sorafenib and intermittent hepatic arterial
infusion chemotherapy using cisplatin for unresectable hepatocellular carcinoma. Methods …